Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BCD-148 Extension Study in Paroxysmal Nocturnal Hemoglobinuria
NCT06987864Phase 3Completed
- Sponsor
- BIOCAD
- Start
- Apr 2020
- Primary completion
- Nov 2022
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of BCD-148 in paroxysmal nocturnal hemoglobinuria (PNH), sponsored by BIOCAD. Started Apr 2020; status: completed.
02
Drugs
BCD-148
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on NCT06987864.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06987864.